SLNO beat EPS expectations by 80.77%
Aug 07, 2025, 10:32 AM
0.00%
What does SLNO do
Soleno Therapeutics, a clinical-stage biopharmaceutical company based in Redwood City, California, focuses on developing novel therapeutics for rare diseases, notably DCCR for Prader-Willi syndrome. DCCR, a once-daily oral tablet, recently completed Phase 3 trials and has received Fast-Track and orphan designations in the U.S. and EU.
Soleno Therapeutics (SLNO) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Soleno Therapeutics's actual EPS was -$0.09, beating the estimate of -$0.47 per share, resulting in a 80.77% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.